Federal regulators have received adverse event filings indicating that two people died after administering unauthorized versions of an experimental obesity medication, CBS News reported, citing documents obtained through public records requests.
The filings submitted to the Food and Drug Administration tie the fatalities to products marketed as retatrutide, an unapproved drug currently under development by pharmaceutical manufacturer Eli Lilly. While federal statutes prohibit the commercial distribution of medications not approved by the agency, unregulated vendors have established an expansive online marketplace offering imitation compounds. The records mark the first known U.S. filings alleging that unauthorized retatrutide use factored into patient fatalities, although the reports remain unverified and it is not established whether the substance caused the deaths.
Details of the Reported Fatalities
According to the FDA records reviewed by CBS News, the first incident took place in July when a medical professional notified the agency that a 41-year-old woman with obesity suffered cardiac arrest. The filer classified retatrutide as a suspect product and noted that the patient had acquired the compound from an unreliable origin. Hospital staff attempted multiple resuscitation measures after she arrived with a dangerously rapid pulse, but she died. The filing noted she was otherwise regarded as healthy, though she was also consuming kava, a botanical beverage known for calming effects, around the time of the medical crisis.
A second report arrived at the agency in September detailing the death of a 49-year-old individual. That filing stated a licensed registered nurse persuaded the patient to acquire the compound through a peptide website, supplied vials, and provided dosage recommendations. The patient subsequently suffered extreme dehydration, severe malnutrition and cardiac arrest, according to the document.
An image accompanying the September submission depicted a vial bearing the branding of AlphaLabs, an outfit offering peptides designated for research purposes only. AlphaLabs owner Joseph Samara initially told CBS News his business did not sell the drug and said the reporter had reached the wrong firm before ending the call. An attorney representing Samara, Sinead Killeen, later stated that the redacted regulatory document lacked lot numbers or customer names necessary to confirm whether the substance originated from AlphaLabs, adding that the packaging depicted differed from current supplies. Killeen extended sympathies to the family and stated that medical professionals should never dispense or recommend research-grade compounds to patients.
Surging Exposure and Industry Pushback
America’s Poison Centers, a nonprofit organization tracking toxic exposures, reported 862 retatrutide exposure incidents during the three months ending in September. That total marks a sharp increase from 460 cases recorded during the preceding three-month span and 249 incidents logged during the first quarter of 2026, CBS News reported.
In clinical trials, legitimate retatrutide has driven substantial weight reduction, prompting heightened consumer interest. In a July announcement, Eli Lilly noted that serious cardiovascular complications occurred less frequently than projected among trial participants receiving the drug and those given placebos. Responding to the adverse event filings, Eli Lilly stated the reports demonstrated the individuals used black-market knockoffs. The company warned that unauthorized formulations frequently contain incorrect dosage levels, unintended active compounds, or harmful contaminants. The drugmaker has initiated legal proceedings against entities marketing unauthorized versions, asserting that illicit products risk damaging public trust in the medication.
Pieter Cohen, an associate professor at Harvard Medical School, told CBS News that federal officials must obtain and test the actual substances administered to the deceased patients, describing the situation as a troubling breakdown of the nation’s drug oversight framework.
What Remains Unknown
The FDA declined to confirm whether investigators have verified the claims in either submission, telling CBS News that it evaluates adverse event filings and collects extra information as required, while typically withholding comment on active compliance reviews. The agency redacted personal identifiers, locations, and the nurse’s license details before releasing the records. It remains unknown whether federal regulators will pursue enforcement actions against the sellers or whether state licensing authorities will open formal disciplinary reviews into the medical personnel referenced in the filings.
